Connecting Data to People

Integrated Testing Strategy for Skin Sensitisation

 

Allergic contact dermatitis (aka., skin sensitisation) accounts for 20% of all contact dermatitis cases and has an estimated annual cost of $200 million. It is also a public health problem, responsible for more than seven million outpatient visits annually. Currently, there are more than 3700 substances that are identified as contact allergens.

Douglas Connect provides an open implementation of the integrated testing strategy (ITS) that assesses skin sensitisation potency based on an approach developed at Proctor and Gamble.

The DC-ITS implementation combines information from three validated alternative assays (DPRA, KeratinoSens and h-CLAT) with in silico predictions for bioavailability using open cheminformatics tools from the community.

DC-ITS allows scientists to evaluate the skin sensitisation hazard of their chemicals using a combination of in vitro and in silico tools. It automatically compensates for the missing experimental data by using predicted values and utilizes the expert-knowledge embedded in the skin sensitization adverse outcome pathway (AOP). More

 

 

Dr Ahmed Abdelaziz
Safety Scientist

 

 

 

 

Rok Predan
Community Manager

 

Please visit our ITS posters during SOT:

Assist—A Platform for Supporting Regulatory Assessment of Chemicals' Toxicity toward Filling REACH Information Gaps
Presented by Ahmed Abdelaziz
Abstract Number/Poster Board number: 1388/P126
Session Title: Bioinformatics and Tox Databases
March 13 1:15pm to 4:30pm
CC Exhibit Hall or Hall A

An Integrated Decision Strategy Development for Skin Sensitization Assessment
Presented by Thomas Exner
Abstract Number/Poster Board number: 2948/P442
Session Title: Quantitative Systems Toxicology
March 15 1:15pm to 4:30pm
CC Exhibit Hall or Hall A

 

DC CONNECTIONS

Latest Tweets

Douglas Connect (2 weeks ago)
https://t.co/BYmTVjxqvr
Douglas Connect (2 weeks ago)
https://t.co/TfiARTZk2m
Douglas Connect (3 weeks ago)
Join us at OpenTox USA 2018, July 11-12, in Raleigh-Durham. Our theme for this year will be: Maximizing the benefit… https://t.co/1pyQhx88Kx
Douglas Connect (3 weeks ago)
This is the first announcement for an additional eChemInfo Training and Innovation Course in Drug Design 3-7 Septe… https://t.co/36eMROXQ6Q
Douglas Connect (4 weeks ago)
Evidence-based medicine has proven its worth. So, how do we now apply it to toxicology? Learn more:… https://t.co/XzRni13iRf

Get in touch

  • Address: Douglas Connect GmbH
    Technology Park Basel
    Hochbergerstrasse 60C
    CH-4057 Basel / Basel-Stadt
    Switzerland
  • Phone: +41 61 851 0170
  • Email: info@douglasconnect.com